/PLUR
PLUR Stock - Pluri Inc.
Healthcare|BiotechnologyNASDAQ
$3.40-1.45%
$0.05 (-1.45%) • Dec 19
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.6
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.97
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+252.9%upside
Target: $12.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PLUR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.37 – $3.43
TARGET (TP)$12.00
STOP LOSS$3.13
RISK/REWARD1:31.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.57
52W High$7.13
52W Low$2.82
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.34M | $326,000 | $287,000 | $234,000 | N/A |
| Gross Profit | $654,000 | $322,000 | $278,000 | $-819,000 | $-1,370,000 |
| Gross Margin | 49.0% | 98.8% | 96.9% | -350.0% | N/A |
| Operating Income | $-22,176,000 | $-22,158,000 | $-27,246,000 | $-41,593,000 | $-50,623,000 |
| Net Income | $-22,583,000 | $-20,888,000 | $-28,321,000 | $-41,242,000 | $-49,865,000 |
| Net Margin | -1690.3% | -6407.4% | -9867.9% | -17624.8% | N/A |
| EPS | $-3.56 | $-3.99 | $-6.18 | $-10.24 | $-14.19 |
Company Overview
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
PLURBeat Rate
50%
Last 14 quarters
Avg Surprise
-241.7%
EPS vs Estimate
Beats / Misses
7/7
Last 12 quarters
Latest EPS
$-0.65
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
-320.8%
$-1.01vs$-0.24
Q3 24
-1962.5%
$-2.98vs$0.16
Q4 24
No data
Q1 25
No data
Q2 25
-28.8%
$-0.94vs$-0.73
Q3 25
-303.1%
$-2.62vs$-0.65
Q4 25
+12.2%
$-0.65vs$-0.74
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 10, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.74 | $-0.65 | +12.2% | ✓ BEAT |
Q3 2025 | Sep 17, 2025 | $-0.65 | $-2.62 | -303.1% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.73 | $-0.94 | -28.8% | ✗ MISS |
Q1 2025 | Feb 11, 2025 | — | $-0.53 | — | — |
Q4 2024 | Nov 12, 2024 | — | $-1.08 | — | — |
Q3 2024 | Sep 18, 2024 | $0.16 | $-2.98 | -1962.5% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.24 | $-1.01 | -320.8% | ✗ MISS |
Q1 2024 | Feb 12, 2024 | — | $-0.96 | — | — |
Q4 2023 | Nov 13, 2023 | — | $-0.96 | — | — |
Q3 2023 | Sep 12, 2023 | $-2.48 | $-1.20 | +51.6% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-2.40 | $-1.52 | +36.7% | ✓ BEAT |
Q1 2023 | Feb 13, 2023 | $-2.56 | $-1.92 | +25.0% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.32 | $-1.52 | -375.0% | ✗ MISS |
Q3 2022 | Sep 21, 2022 | $-0.35 | $-2.24 | -540.0% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.36 | $-0.31 | +13.9% | ✓ BEAT |
Q1 2022 | Feb 7, 2022 | $-0.38 | $-0.34 | +10.5% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-0.41 | $-0.36 | +12.2% | ✓ BEAT |
Q3 2021 | Sep 13, 2021 | $-0.40 | $-0.46 | -15.0% | ✗ MISS |
Latest News
Pluri Appoints Alejandro Weinstein As Chairman
➖ NeutralBenzinga•Dec 9, 2025, 01:35 PM
Pluri Q1 EPS $(0.65) Beats $(0.74) Estimate, Sales $316.000K Miss $638.000K Estimate
➖ NeutralBenzinga•Nov 12, 2025, 10:20 PM
Pluri's Subsidiary Coffeesai Partners With Chiapas Coffee Institute To Launch Cell-Based Coffee Manufacturing In Mexico
📈 PositiveBenzinga•Oct 8, 2025, 01:12 PM
Pluri Q4 EPS $(1.00) Misses $(0.73) Estimate, Sales $398.000K Miss $400.000K Estimate
📉 NegativeBenzinga•Sep 17, 2025, 09:34 PM
Pluri Inc Notified Of Nasdaq Non-Compliance Over Audit Committee Independence
📉 NegativeBenzinga•Sep 12, 2025, 12:03 PM
Frequently Asked Questions about PLUR
What is PLUR's current stock price?
Pluri Inc. (PLUR) is currently trading at $3.40 per share. The stock has moved -1.45% today.
What is the analyst price target for PLUR?
The average analyst price target for PLUR is $12.00, based on 1 analyst.
What sector is Pluri Inc. in?
Pluri Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PLUR's market cap?
Pluri Inc. has a market capitalization of $0.02 billion, making it a small-cap company.
Does PLUR pay dividends?
No, Pluri Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANTX
AN2 Therapeutics, Inc.
$1.12
Mkt Cap: $0.0B
BOLD
Boundless Bio, Inc.
$1.22
Mkt Cap: $0.0B
IBIO
iBio, Inc.
$1.98
Mkt Cap: $0.0B
INTS
Intensity Therapeutics, Inc.
$0.41
Mkt Cap: $0.0B
ITRM
Iterum Therapeutics plc
$0.37
Mkt Cap: $0.0B
JSPR
Jasper Therapeutics, Inc.
$1.86
Mkt Cap: $0.0B
NXTC
NextCure, Inc.
$11.38
Mkt Cap: $0.0B
PSTV
Plus Therapeutics, Inc.
$0.57
Mkt Cap: $0.0B
QTTB
Q32 Bio Inc.
$2.96
Mkt Cap: $0.0B
SABS
SAB Biotherapeutics, Inc.
$3.99
Mkt Cap: $0.0B
Explore stocks similar to PLUR for comparison